LV12018B - PREPARATION PROCESS OF 2-METHYL-THENO-BENZODIAZEPINE AND ITS CRYSTALLINE FORMS - Google Patents

PREPARATION PROCESS OF 2-METHYL-THENO-BENZODIAZEPINE AND ITS CRYSTALLINE FORMS Download PDF

Info

Publication number
LV12018B
LV12018B LVP-97-163A LV970163A LV12018B LV 12018 B LV12018 B LV 12018B LV 970163 A LV970163 A LV 970163A LV 12018 B LV12018 B LV 12018B
Authority
LV
Latvia
Prior art keywords
olanzapine
less
methyl
active ingredient
quot
Prior art date
Application number
LVP-97-163A
Other languages
English (en)
Latvian (lv)
Other versions
LV12018A (lv
Inventor
Charles Arthur Bunnell
Barry Arnold Hendriksen
Samuel Dean Larsen
Original Assignee
Eli Lilly And Company
Lilly Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV12018(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company, Lilly Industries Limited filed Critical Eli Lilly And Company
Publication of LV12018A publication Critical patent/LV12018A/xx
Publication of LV12018B publication Critical patent/LV12018B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
LVP-97-163A 1995-03-24 1997-09-08 PREPARATION PROCESS OF 2-METHYL-THENO-BENZODIAZEPINE AND ITS CRYSTALLINE FORMS LV12018B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24
PCT/US1996/003917 WO1996030375A1 (fr) 1995-03-24 1996-03-22 Formes cristalline de 2-methyl-thieno-benzodiazepine et procede correspondant

Publications (2)

Publication Number Publication Date
LV12018A LV12018A (lv) 1998-04-20
LV12018B true LV12018B (en) 1998-09-20

Family

ID=23621056

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-97-163A LV12018B (en) 1995-03-24 1997-09-08 PREPARATION PROCESS OF 2-METHYL-THENO-BENZODIAZEPINE AND ITS CRYSTALLINE FORMS

Country Status (49)

Country Link
US (1) US5736541A (fr)
EP (3) EP1445259B1 (fr)
JP (1) JPH11502535A (fr)
KR (1) KR100399688B1 (fr)
CN (1) CN1065536C (fr)
AP (1) AP828A (fr)
AR (2) AR010448A1 (fr)
AT (4) AT406771B (fr)
AU (1) AU706471B2 (fr)
BG (1) BG62619B1 (fr)
BR (1) BR9607790A (fr)
CA (1) CA2214005C (fr)
CH (1) CH690579A5 (fr)
CO (1) CO4650278A1 (fr)
CZ (1) CZ292688B6 (fr)
DE (4) DE69630324T2 (fr)
DK (4) DK1095941T3 (fr)
EA (1) EA000149B1 (fr)
EE (1) EE03489B1 (fr)
EG (1) EG23659A (fr)
ES (3) ES2266719T3 (fr)
FI (1) FI973750A0 (fr)
GB (1) GB2313835B (fr)
HK (1) HK1013988A1 (fr)
HU (1) HU224989B1 (fr)
IL (1) IL117610A (fr)
IS (1) IS1896B (fr)
LT (1) LT4349B (fr)
LU (1) LU90096B1 (fr)
LV (1) LV12018B (fr)
MY (1) MY114701A (fr)
NO (1) NO314663B1 (fr)
NZ (1) NZ306110A (fr)
OA (1) OA10510A (fr)
PA (1) PA8353701A1 (fr)
PE (1) PE44897A1 (fr)
PL (1) PL183723B1 (fr)
PT (3) PT733635E (fr)
RO (1) RO118872B1 (fr)
SE (1) SE9703205D0 (fr)
SI (4) SI1095941T1 (fr)
SK (1) SK284143B6 (fr)
SV (1) SV1996000031A (fr)
TR (1) TR199701017T1 (fr)
TW (2) TW442488B (fr)
UA (1) UA44765C2 (fr)
WO (1) WO1996030375A1 (fr)
YU (1) YU49478B (fr)
ZA (2) ZA962344B (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
WO1997011700A1 (fr) * 1995-09-29 1997-04-03 Eli Lilly And Company Methode de traitement d'un tic chronique
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
WO1997035585A1 (fr) * 1996-03-25 1997-10-02 Eli Lilly And Company Methode d'anesthesie
KR20000004966A (ko) * 1996-03-25 2000-01-25 피터 지. 스트링거 편두통 치료 방법
IL126203A (en) * 1996-03-25 2002-12-01 Lilly Co Eli A synergistic painkiller that contains olenzapine and another painkiller
IL126064A0 (en) * 1996-03-25 1999-05-09 Lilly Co Eli Method for treating pain
EA001881B1 (ru) * 1996-09-23 2001-10-22 Эли Лилли Энд Компани Форма d дигидрата оланзапина
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
WO1998046596A1 (fr) * 1997-04-15 1998-10-22 Eli Lilly And Company Methode destinee a produire des effets neuro-protecteurs
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
EP1155696B1 (fr) * 1997-04-15 2004-03-03 Eli Lilly And Company Utilisation de l'olanzapine pour la fabrication d'un médicament pour la neuroprotection
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
TR200100885T2 (tr) * 1998-09-30 2001-08-21 Eli Lilly And Company 2-Metil-tieno-benzodiazepin formülasyonu
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
NZ519926A (en) * 1999-12-28 2004-02-27 Cipla Ltd New polymorphic forms of olanzapine
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
BR0114031A (pt) * 2000-08-31 2003-09-09 Reddy S Lab Ltd Processo para a preparação de hidratos de olanzapina e sua conversão em formas cristalinas de olanzapina
AU2001282913A1 (en) * 2000-09-08 2002-03-22 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
EP1440074A1 (fr) * 2001-10-29 2004-07-28 Dr. Reddy's Laboratories Ltd. Dihydrate-ii d'olanzapine: son procede de preparation et son utilisation
AU2002367119A1 (en) 2001-12-24 2003-07-15 Sun Pharmaceutical Industries Limited Crystalline form I of 2-methyl-4-(4-methyl-1-piperazinyl) 10H thieno [2,3-b][1,5]benzodiazepine
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
WO2004089313A2 (fr) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Nouvelles formes de l'olanzapine et methodes de traitement associees
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
AU2003237305A1 (en) 2002-05-31 2003-12-19 Geneva Pharmaceuticals, Inc. Process of preparation of olanzapine form i
JP2006500377A (ja) * 2002-06-21 2006-01-05 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 改善された溶解性を有する医薬組成物
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
US7323459B2 (en) 2002-12-24 2008-01-29 Teva Pharmaceutical Industries Ltd. Crystal forms, methods for their preparation and method for preparation of olanzapine
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
US20040229896A1 (en) * 2003-03-12 2004-11-18 Toth Zoltan G. Stable pharmaceutical compositions of desloratadine
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
WO2005049090A2 (fr) * 2003-11-18 2005-06-02 3M Innovative Properties Company Compositions d'administration medicamenteuse transdermique renfermant de l'olanzapine
CN1906201A (zh) * 2003-12-22 2007-01-31 特瓦制药工业有限公司 合成奥氮平的方法
WO2005070938A1 (fr) 2004-01-27 2005-08-04 Synthon B.V. Sels stables d'olanzapine
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
US7829700B2 (en) 2004-09-06 2010-11-09 Shasun Chemicals And Drugs Limited Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
AU2005307797B2 (en) * 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
EP1838716B1 (fr) 2005-01-05 2011-06-01 Eli Lilly And Company Dihydrate d'olanzapine pamoate
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
BRPI0608484E2 (pt) * 2005-03-21 2014-10-29 Reddys Lab Ltd Dr Processo de preparação da forma i cristalina de olanzapina
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
EP1919923A1 (fr) * 2005-08-17 2008-05-14 Synthon B.V. Procede de fabrication d'olanzapine de forme i
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (fr) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Nouvelles methodes de synthese de la forme-i de l'olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (fr) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Processus de purification d'olanzapine
AU2011293502B2 (en) 2010-08-23 2015-03-19 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (fr) 2011-05-04 2012-11-15 Zentiva K.S. Composition pharmaceutique d'olanzapine de forme 1 à administration par voie orale
PL2888590T3 (pl) 2012-08-21 2020-11-30 Janssen Pharmaceutica Nv Przeciwciała dla olanzapiny i ich zastosowanie
ES2733963T3 (es) 2012-08-21 2019-12-03 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de olanzapina y uso de los mismos
ES2926662T3 (es) 2012-08-21 2022-10-27 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de risperidona y uso de los mismos
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CN103848847B (zh) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 奥氮平晶型及其制备方法和用途
WO2023139531A1 (fr) 2022-01-20 2023-07-27 Teva Pharmaceuticals International Gmbh Olanzapine, ses compositions et méthodes d'utilisation associées

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (fr) 1977-07-20 1981-03-10 George K. E. Gregory Emballages
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
TW268005B (fr) * 1992-05-29 1996-01-11 Lilly Industries Ltd
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
LV12018A (lv) 1998-04-20
TR199701017T1 (xx) 1998-01-21
ATE331719T1 (de) 2006-07-15
GB2313835A (en) 1997-12-10
PE44897A1 (es) 1997-10-22
SK121897A3 (en) 1998-03-04
GB2313835B (en) 1998-09-16
SE9703205L (sv) 1997-09-05
EP0733635A1 (fr) 1996-09-25
BR9607790A (pt) 1998-07-07
NZ306110A (en) 1998-09-24
OA10510A (en) 2002-04-24
PL183723B1 (pl) 2002-07-31
EA000149B1 (ru) 1998-10-29
ES2159346T3 (es) 2001-10-01
DE69630324T2 (de) 2004-07-29
UA44765C2 (uk) 2002-03-15
ES2266719T3 (es) 2007-03-01
AP9701065A0 (en) 1997-10-31
AR010448A1 (es) 2000-06-28
DE69636313D1 (de) 2006-08-10
AT406771B (de) 2000-08-25
KR19980703188A (ko) 1998-10-15
AR002719A1 (es) 1998-04-29
EE9700232A (et) 1998-04-15
CZ292688B6 (cs) 2003-11-12
DK1095941T3 (da) 2004-02-16
EP0733635B1 (fr) 2001-08-16
NO974365D0 (no) 1997-09-22
WO1996030375A1 (fr) 1996-10-03
RO118872B1 (ro) 2003-12-30
ES2208220T3 (es) 2004-06-16
FI973750A (fi) 1997-09-22
ATA902196A (de) 2000-01-15
EP1095941A1 (fr) 2001-05-02
DK1445259T3 (da) 2006-10-16
EP1445259B1 (fr) 2006-06-28
SI9620040B (sl) 2002-02-28
ATE204280T1 (de) 2001-09-15
SI1445259T1 (sl) 2006-10-31
MX9707183A (es) 1997-11-29
ZA962342B (en) 1997-09-22
CA2214005C (fr) 2001-07-03
YU17796A (sh) 1999-03-04
DE69630324D1 (de) 2003-11-13
SE9703205D0 (sv) 1997-09-05
SV1996000031A (es) 1998-03-27
DE69614426D1 (de) 2001-09-20
BG62619B1 (bg) 2000-03-31
IL117610A (en) 2001-08-26
HUP9802824A3 (en) 2000-01-28
DE69636313T2 (de) 2007-05-31
SK284143B6 (sk) 2004-10-05
CZ300097A3 (en) 1997-12-17
FI973750A0 (fi) 1997-09-22
CA2214005A1 (fr) 1996-10-03
HUP9802824A2 (hu) 1999-06-28
DK108997A (da) 1997-11-12
PA8353701A1 (es) 1998-09-18
PT1445259E (pt) 2006-10-31
IL117610A0 (en) 1996-07-23
HU224989B1 (en) 2006-05-29
BG101900A (en) 1999-03-31
NO314663B1 (no) 2003-04-28
KR100399688B1 (ko) 2004-02-18
PT1095941E (pt) 2004-02-27
SI0733635T1 (en) 2002-06-30
GB9719819D0 (en) 1997-11-19
CO4650278A1 (es) 1998-09-03
YU49478B (sh) 2006-05-25
JPH11502535A (ja) 1999-03-02
AP828A (en) 2000-04-28
PT733635E (pt) 2001-12-28
EE03489B1 (et) 2001-08-15
LT4349B (lt) 1998-05-25
LU90096B1 (fr) 1997-07-22
SI1095941T1 (en) 2003-12-31
ZA962344B (en) 1997-09-22
DE19681286T1 (de) 1998-04-02
LT97148A (en) 1998-01-26
CN1065536C (zh) 2001-05-09
EP1445259A1 (fr) 2004-08-11
US5736541A (en) 1998-04-07
TW442488B (en) 2001-06-23
AU5427996A (en) 1996-10-16
DE69614426T2 (de) 2002-05-23
ATE251627T1 (de) 2003-10-15
IS1896B (is) 2003-10-20
TW513432B (en) 2002-12-11
CN1179160A (zh) 1998-04-15
EA199700262A1 (ru) 1998-02-26
NO974365L (no) 1997-09-22
EP1095941B1 (fr) 2003-10-08
DK0733635T3 (da) 2001-10-08
EG23659A (en) 2007-03-26
HK1013988A1 (en) 1999-09-17
AU706471B2 (en) 1999-06-17
SI9620040A (sl) 1998-06-30
IS4564A (is) 1997-09-22
CH690579A5 (de) 2000-10-31
MY114701A (en) 2002-12-31
PL322501A1 (en) 1998-02-02

Similar Documents

Publication Publication Date Title
CA2214005C (fr) Formes cristalline de 2-methyl-thieno-benzodiazepine et procede correspondant
AU720366B2 (en) Olanzapine dihydrate D
AU719441B2 (en) Intermediates and process for preparing olanzapine
WO1996038151A1 (fr) Procede de traitement du dysfonctionnement cognitif
MXPA97007183A (en) A process and glass forms of 2-methyl-tieno-benzodiazep
US6506746B2 (en) Method for treating cognitive dysfunction